AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 5 - (NewsRx.com & NewsRx.net) -- The first patient has been vaccinated in a New York University (NYU) Medical Center clinical trial of a new cancer vaccine.
The vaccine is designed to prevent patients who have already had a kind of cancer called follicular lymphoma from having a recurrence of the disease.
Follicular lymphoma causes tumors to grow in the lymph nodes. "Patients with lymphoma are very young, usually in their thirties, so they will die of this disease," explained Giorgio Inghirami, MD, associate professor of pathology, who is leading the clinical trial. Even with treatment such as chemotherapy, lymphoma redevelops in the patient in nearly 100% of cases. About 40,000 new cases of this type of cancer are diagnosed every year in the United States.
The lymphoma vaccine is designed to eliminate any cancer cells that are left over after chemotherapy, and therefore prevent the disease from recurring. The vaccine, which was developed over the last 10 years at the U.S. National Cancer Institute, has undergone Phase I and Phase II trials already, which are designed to show only that it is safe for use in first animals and then humans.
In these early trial stages, results were so dramatic that ...
Source: HighBeam Research, New cancer vaccine trial to begin.